Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

B cells or B lymphocytes are an important part of the body's immune system. When healthy B cells are infected with the Epstein-Barr virus (EBV), they undergo growth transformation, a process that immortalizes B cells, leading to their uncontrolled proliferation.

7 Aug 2023

IN8bio opens new cancer research lab in Birmingham's Pepper Place

Birmingham's Pepper Place has a striking new addition to its teeming farmers' market and noted food offerings -; a multimillion-dollar cancer research laboratory.

1 Aug 2023

Two new compounds can block cancer cell’s escape route

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying.

27 Jul 2023

Henry Ford Health researcher wins grant to study circulating cell-free DNA methylation as a tool for glioma detection

Houtan Noushmehr, Ph.D., a researcher at Henry Ford Health, has been awarded a prestigious R01 grant of nearly $2.9M from the National Institutes of Health (NIH) to support a research project titled, "Circulating cell-free DNA methylation as an accurate tool for detection and clinical follow-up of glioma."

27 Jul 2023

Targeting the "don't eat me" signal may improve immunotherapy for glioblastoma

"Don't eat me!" That's how one might translate the signal that the cancer cells in a glioblastoma send to the macrophages (white blood cells specialized in removing dead and dying cellular matter) in the brain.

19 Jul 2023

Elias family's gift to MD Anderson will help advance brain tumor and cancer neuroscience research

The University of Texas MD Anderson Cancer Center today announced a $16.25 million gift from Howard and Susan Elias to accelerate brain tumor and cancer neuroscience research, an emerging field focused on integrating the role of the nervous system in cancer.

18 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

Research establishes ERβ as a tumor suppressor in inflammatory breast cancer

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "ERβ as a mediator of estrogen signaling in inflammatory breast cancer."

3 Jul 2023

Ancient retrovirus may be responsible for aggressive brain cancers

The median length of survival after diagnosis of glioblastoma is 14 months, but some of these brain tumors are more aggressive and resistant to treatment than others, and a new study from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests reactivation of an ancient retrovirus may be at least partly to blame.

3 Jul 2023

Glioblastoma cells found to have ‘critical point’ between order and disorder

Glioblastoma is the most aggressive form of brain cancer. Despite decades of major efforts and clinical trials, the tumor's survival rate has remained stagnant.

28 Jun 2023

Neurons in remote brain regions drive glioblastoma infiltration

Glioblastoma (GBM) is the most aggressive and lethal form of brain tumor. Despite treatment, GBM recurrence is inevitable and tends to occur outside surgical margins or in locations remote to the primary tumor, highlighting the central role played by tumor infiltration in this malicious disease.

28 Jun 2023

UH and CWRU research teams win Collaborative Science Pilot Awards

Three University Hospitals (UH) and Case Western Reserve University School of Medicine research teams recently received Collaborative Science Pilot Awards. The teams each received $50,000, funded by both institutions.

28 Jun 2023

Stanford and Intonation partner to develop new treatments for neuroendocrine tumors

Stanford University's Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.

23 Jun 2023

Radiation combined with cancer-targeting virus therapy more effective in fighting brain tumors

Combining a cancer-targeting virus with radiation to treat brain cancer in mice was more effective than either therapy on its own according to University of Alberta research, providing hope for new treatments that combine immunotherapy with traditional surgery, chemotherapy or radiation.

20 Jun 2023

Innovative method to map specific DNA markings could be used for early cancer detection

Researchers from the Perelman School of Medicine at the University of Pennsylvania have invented a new way to map specific DNA markings called 5-methylcytosine (5mC) which regulate gene expression and have key roles in health and disease.

15 Jun 2023

Researchers identify a potential breakthrough in glioblastoma treatment

In a recently published manuscript, Howard Colman, MD, PhD, Jon M. Huntsman Presidential Professor of Neuro-Oncology and co-leader of the Neurologic Cancers Disease Center and the Experimental Therapeutics CCSG program at Huntsman Cancer Institute, identified a potential breakthrough in glioblastoma treatment.

12 Jun 2023

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to selectively replicate in and destroy cancer tissue, in combination with fractionated stereotactic radiosurgery among patients who are undergoing resection of a recurrent high-grade astrocytoma brain tumor.

8 Jun 2023

Glioblastoma News and Research

Further Reading

Researchers uncover genetic machinery responsible for EBV-induced B cell growth transformation

IN8bio opens new cancer research lab in Birmingham's Pepper Place

Two new compounds can block cancer cell’s escape route

Henry Ford Health researcher wins grant to study circulating cell-free DNA methylation as a tool for glioma detection

Targeting the "don't eat me" signal may improve immunotherapy for glioblastoma

Elias family's gift to MD Anderson will help advance brain tumor and cancer neuroscience research

Using a vaccine to boost the response of engineered T cells

Research establishes ERβ as a tumor suppressor in inflammatory breast cancer

Ancient retrovirus may be responsible for aggressive brain cancers

Glioblastoma cells found to have ‘critical point’ between order and disorder

Neurons in remote brain regions drive glioblastoma infiltration

UH and CWRU research teams win Collaborative Science Pilot Awards

Stanford and Intonation partner to develop new treatments for neuroendocrine tumors

Radiation combined with cancer-targeting virus therapy more effective in fighting brain tumors

Innovative method to map specific DNA markings could be used for early cancer detection

Researchers identify a potential breakthrough in glioblastoma treatment

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Novel technology helps analyze tumor growth in another dimension

New method can kill aggressive brain tumors

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News